Syntara Limited
Syntara Limited
Your view on SNT.AX
Overview
What the company does, where it operates, and who runs it.
About Syntara Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gary Jonathan Phillips
- Headquarters
- 20A Rodborough Road, Frenchs Forest, NSW, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gary Jonathan Phillips
- Headquarters
- 20A Rodborough Road, Frenchs Forest, NSW, AU
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry.
Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders.
Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates.
These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation.
The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Syntara Limited, and the rating behind it. SNT.AX last traded at AUD 0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Syntara Limited. Starting points for Syntara Limited: EPS -AUD 0.0051, beta 0.17 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Syntara Limited. Syntara Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Syntara Limited. Trailing twelve-month EPS for Syntara Limited stands at -AUD 0.0051. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Syntara Limited. Syntara Limited has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Syntara Limited valued side by side against its closest peers. Syntara Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Syntara Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Syntara Limited executives and directors. Shares of Syntara Limited have traded between AUD 0.02 and AUD 0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Syntara Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Syntara Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Syntara Limited. Coverage tracks Syntara Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.